Imatinib Teva

Imatinib, the active ingredient in Imatinib Teva, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is employed in the treatment of chronic myeloid leukemia and gastrointestinal stromal tumors, targeting malignant cells in adult patients.

GNH USA supplies Imatinib Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring consistent quality, regulatory compliance, and reliable global distribution.

Imatinib acts on malignant cells driven by BCR‑ABL, c‑KIT or PDGFR signaling pathways.

Chronic Myeloid Leukemia: provides targeted inhibition of leukemic cell proliferation. Gastrointestinal Stromal Tumor: controls tumor growth by blocking KIT‑driven signaling. Philadelphia‑positive Acute Lymphoblastic Leukemia: offers targeted therapy to improve remission rates.

Imatinib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Fluid retention or peripheral edema - Muscle cramps or weakness - Fatigue - Diarrhea - Rash or mild skin irritation

Serious or Rare Side Effects: - Hepatotoxicity (elevated liver enzymes or hepatitis) - Severe neutropenia or thrombocytopenia - Cardiac failure or reduced left‑ventricular function - Pulmonary arterial hypertension - Severe skin reactions such as Stevens‑Johnson syndrome - Tumor lysis syndrome in high‑burden disease

Before initiating therapy, clinicians should assess baseline organ function and monitor patients regularly.

Monitor blood counts: perform complete blood count at baseline and periodically. Assess liver function: check hepatic enzymes before treatment and during therapy. Evaluate cardiac status: perform ECG or echocardiogram in patients with cardiac risk factors. Avoid in severe hypersensitivity: discontinue if anaphylactic reaction occurs. Use caution in renal impairment: adjust monitoring in patients with reduced clearance. Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Imatinib interacts with several medicines that affect its metabolism or pharmacodynamic profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase imatinib exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic levels. - Concomitant use with potent P‑glycoprotein inhibitors (e.g., verapamil): may raise plasma concentrations.

Moderate Interactions (Monitor Closely): - CYP3A4 substrates with narrow therapeutic index (e.g., midazolam, tacrolimus): monitor levels. - Anticoagulants such as warfarin: watch INR for potential changes. - Diuretics (e.g., furosemide): monitor electrolytes and renal function.